Spindle cell variant of medullary thyroid carcinoma: a clinicopathologic study of four cases

Yan Xia Wang
Fourth Military Medical University: Air Force Medical University

Shoujing Yang (✉ yangsj@fmmu.edu.cn)
Fourth Military Medical University

Short report

Keywords: Spindle cell, Thyroid carcinoma, Morphology, Immunophenotype

DOI: https://doi.org/10.21203/rs.3.rs-290368/v1

License: ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

Medullary thyroid carcinoma (MTC) is a malignant tumor derived from C cells. It accounts for about 10% of all thyroid malignancies. More than 14 histological variants have been described. Among them, spindle cell variant is extremely rare.

Case presentation

Here we describe 4 cases of spindle cell variant of MTC collected from 2012 to 2019. Ultrasound showed solid and hypoechoic nodules. Three patients underwent total thyroidectomy and regional lymph node dissection, and 1 patient underwent thyroid mass resection. Histologically, the tumors showed spindle shaped cells in bundles or interlaced arrangement, separated by hyalinised fibrous stroma that contained amyloid deposits. Immunohistochemistry showed that the tumor cells were positive for calcitonin, chromogranin A, synaptophysin, CD56, and TTF-1, but negative for other lineage-specific markers.

Conclusions

We report 4 rare cases of spindle cell variant of MTC. Due to its rarity and special morphology, the diagnosis of spindle cell variant MTC relies on its morphology and immunohistochemical markers to avoid misdiagnosis.

Background

Medullary thyroid carcinoma (MTC) is a malignant tumor with neuroendocrine characteristics, originated from parafollicular C cells secreting calcitonin. It accounts for 5–10% of all thyroid malignancies. Most patients are asymptomatic with lymph node metastasis in the early stage or distant metastasis in the later stage, and its mortality accounts for 13.4% of all thyroid malignancies. More than 14 histological subtypes of MTC have been described in current WHO classification. Spindle cell variant MTC is a rare variant, and only 5 cases have been reported to date [1–5]. It is easy to mistake for other lesions due to its rarity and spindle cell morphology. Here we report 4 cases of MTC with predominantly spindle cell pattern in clinical and pathological features to enhance understanding of this type of MTC.

Materials And Methods

Case presentation

Four cases of spindle cell variant MTC were collected from 2012 to 2019, including 2 males and 2 females, aged 26 to 54 years old. Patients visited hospital with the accidental discovery of painless neck mass accompanied by gradual enlargement. On clinical examination, mass was diffuse and firm, moving with deglutition. Family history was unremarkable. Biochemical examination showed normal serum parathormone level. Thyroid function test was within normal range. Ultrasound showed solid and
hypoechoic nodules of 2~6 cm in diameter. Two cases occurred in the left lobe of thyroid, and another 2
cases occurred in the right lobe of thyroid, including 1 case with gravelly calcification and 1 case with
ipsilateral lymph node metastasis.

**Methods**

The tissue samples were fixed with 10% neutral formalin and embedded in paraffin. Tissue sections of
4~5 μm thickness were prepared and stained with hematoxylin and eosin (H&E), and additional sections
were stained with Congo red. Immunohistochemical staining was performed using Dako EnVision
Peroxidase detection system on Roche Ventana Benchmark XT autostainer (Ventana Medical Systems,
Tucson, AZ). The primary antibodies panel consisted of calcitonin (CT) (clone SP17, Ready-to-Use),
chromogranin A (CgA) (SP12, Ready-to-Use), synaptophysin (Syn) (SY38, 1:100), CD56 (1B6, 1:50,
Novocastra, Newcastle upon Tyne, UK), TTF-1 (SPT24, prediluted), Thyroglobulin (TG) (2H11+6E1), Ki-67
(MIB-1, 1:100), carcinoembryonic antigen (CEA) (12-140-10, Ready-to-Use), cytokeratin (AE1/AE3, Ready-
to-Use), epithelial membrane antigen (EMA) (E29, 1:100), vimentin (V9, 1:100), desmin (D33, 1:160),
alpha-smooth muscle actin (SMA) (IA4, 1:100, Dako), HMB45 (HMB-45, 1:50), S-100 protein
(polyclonal,1:200), HBME-1 (HBME-1, Ready-to-Use), galectin-3 (9C4, Ready-to-Use), CK19 (A53-B/A2.26,
Ready-to-Use), and CD99 (12E7, 1:50) .Unless otherwise stated, all antibodies were mouse monoclonal
and from DAKO Corporation (Dako North America, Inc., Carpinteria, CA, USA). Appropriate positive and
negative controls were run in parallel.

**Results**

**Pathological morphology**

Grossly, the mass of the four patients had clear boundary, 2~6cm in diameter, solid shape, soft texture
and grayish-white or grayish-brown in color. Among them, the capsule of the tumor was intact in 3
patients, and incomplete in 1 patient.

Histological examination of the specimens showed that the tumors consisted predominantly of
monomorphic spindle cells, arranged in fascicles or interweaves (Fig. 1a), separated by fibrovascular or
amyloid stroma (Fig .1b). Tumor cells showed short or long spindle nuclei, abundant cytoplasm,
inconspicuous nucleoli and rare mitoses (Fig. 1c). The boundary between tumor tissue and peripheral
thyroid tissue was clear.

**Congo Red Amyloid Stain**

Tumor tissue were positive (3/3) for Congo red staining.

**Immunohistochemistry**

The tumor cells were positive for CT (Fig. 2a), CgA (Fig. 2b), Syn (Fig. 2c), CD56 (Fig. 2d), and TTF-1 (Fig.
2e) in all 4 cases. In addition, the tumor cells were also positive for AE1/AE3 (2/2), CEA (3/3), EMA (1/1)

and vimentin (2/2). Other markers such as TG, Desmin, SMA, S-100, galectin-3, CK19, HBME-1, and CD99 were negative. The Ki-67 proliferative index of these tumors ranged approximately 3%~10% (Fig. 2f).

**Treatment and follow-up**

Three patients underwent total thyroidectomy and regional lymph node dissection, and 1 patient underwent thyroid mass resection. After a follow up of 7~84 months, all four patients were alive.

**Discussion**

Spindle cell variant MTC is a rare type of MTC, and only 5 cases have been reported in literatures thus far [1–5]. We reviewed 99 cases of MTC confirmed in our hospital from 2012 to 2019, only 4 cases spindle cell variant MTC meet the criteria, accounting for 4% of all MTC.

MTC is a neuroendocrine tumor, accounting for 5%~10% of thyroid malignant tumors [6]. The clinical symptoms of spindle cell variant MTC are consistent with MTC. MTC patients generally have no specific clinical symptoms, only presenting with a painless thyroid mass, sometimes presenting with intractable diarrhea, facial flushing or other neuroendocrine symptoms. In addition, serum calcitonin (sCT) is the most sensitive and specific marker for preoperative diagnosis of MTC [7], and serum CEA is synchronous with sCT in some MTC patients [8, 9], which is of reference value for diagnosis and prognosis of the disease. When the tumor causes compression or invasion to the surrounding tissues, the corresponding clinical symptoms may appear, and lymph node metastasis is easy to occur in the early stage. All the patients in our series presented with cervical mass without increase of sCT and CEA.

Histological diagnosis of MTC depends on its cytological feature, growth pattern, and amyloid deposition, as well as its immunophenotype. MTC with predominant spindle cell morphology is seen less commonly. The spindle cell variant MTC consists mainly of irregularly arranged bundles or interlaced spindle cells in which the stroma is separated by fibrous stroma or amyloid. Amyloid deposition is not a necessary condition for MTC diagnosis, since amyloid may not be present in atypical cases. The tumor cells showed short or long spindle nuclei, abundant cytoplasm, inconspicuous nucleoli and rare mitoses, as well as clear boundaries with surrounding tissues. Immunohistochemically, the most sensitive markers for the neoplasm are CT and calcitonin gene-related peptide, although they are not specific because they also can be found in endocrine tumors of nonthyroid origin, such as islet cell tumors and intestinal neuroendocrine carcinomas. In addition, MTC cells also are immunoreactive for cytokeratins, neuron-specific enolase, Syn, CEA, and CgA, whereas they are not stained by TG. In our cases, the tumors showed spindle cell morphology, the positive expressions of TTF-1, CT, CgA, Syn and CD56 and amyloid deposition, confirming the diagnosis as spindle cell variant MTC, which were consistent with those reported in the literature[10].

Spindle cell variant MTC is necessary to differentiate it from other primary or secondary thyroid tumors that show spindle cell morphology[11]. Other spindle cell tumors occurring in the thyroid gland, such as spindle cell atypical thyroid adenoma, spindle epithelial tumor with thymus-like differentiation, poorly
differentiated thyroid carcinoma, and anaplastic thyroid carcinoma, may show spindle cell morphology and positive expression of epithelial cell markers, TTF-1 and TG, but they are negative for neuroendocrine markers. Therefore, it is easy to distinguish these tumors by comprehensive staining of CT, TTF-1, CgA, Syn and CD56. Also, spindle cell variant MTC can mimic some spindle cell mesenchymal tumors occurring in the thyroid gland, such as leiomyoma, peripheral schwannoma, and spindle cell melanoma. These tumors have specific markers, but are negative for neuroendocrine markers. Therefore, the morphology in conjunction with immunohistochemistry is sufficient to render a diagnosis of these tumors.

Surgical treatment is still the best treatment for spindle cell variant MTC. When surgical treatment is difficult to control, the efficacy of radioactive iodine treatment, in vitro irradiation or chemotherapy is poor. Therefore, early detection and treatment is the most effective way to improve the therapeutic effect. In our series, all patients received local resection or regional lymph node dissection. During follow-up of 7 ~ 84 months in our series, all patients were alive and had no recurrence.

In conclusion, spindle cell variant MTC is an extremely rare histological subtype. It is easy to diagnose and differentiate from other spindle cell lesions of thyroid by histological morphology, immunohistochemical staining with CT, CgA, Syn, CD56, and TTF-1.

**Abbreviations**

MTC: Medullary thyroid carcinoma; WHO: World Health Organization; CT: calcitonin; CgA: chromogranin A; Syn: synaptophysin; TG: Thyroglobulin; CEA: carcinoembryonic antigen; EMA: epithelial membrane antigen;

**Declarations**

**Acknowledgements**

Not applicable.

**Funding**

This present study was funded by the National Nature Science Foundation of China (grant nos. 81800046)

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

**Authors’ Contributions**
Yan Xia Wang: data collection and drafting. Yang Shoujing: pathological diagnosis, guiding paper writing and revision. All authors approved the manuscript.

**Ethics approval and consent to participate**

Not applicable

**Consent for publication**

Written informed consent was obtained from the patient for the publication of short report.

**Competing interests**

The authors declare that they have no competing interests.

**References**

1. Ibarrola de Andres C, Castellano Megias VM, Ballestin Carcavilla C, Alberti Masgrau N, Perez Barrios ADe Agustin PA. Hepatic metastases from the spindle cell variant of medullary thyroid carcinoma: report of a case with diagnosis by fine needle aspiration biopsy. Acta cytologica. 2001; 45: 1022-6.

2. Laforga JBAranda FI. Pseudoangiosarcomatous features in medullary thyroid carcinoma spindle-cell variant. Report of a case studied by FNA and immunohistochemistry. Diagnostic cytopathology. 2007; 35: 424-8.

3. Satylganov I. [Spindle-cell variant of thyroid medullary carcinoma with favourable prognosis]. Arkhiv patologii. 2000; 62: 42-4.

4. Blonk DI, Talerman AVisser-van Dijk MN. The cytology of medullary carcinoma of the thyroid with spindle cell pattern. Archiv fur Geschwulstforschung.1978; 48: 313-7.

5. Das A, Nargotra N, Singh S, Deepak RKTyagi I. Rare Presentation of Medullary Carcinoma of Thyroid with Predominant Spindle Cell Pattern & abundant Calcification. Annals of Pathology and Laboratory Medicine. 2016; 03: C130-4.

6. Rusinek D, Chmielik E, Krajewska J, Jarzab M, Oczko-Wojciechowska M, Czarniecka A, Jarzab B. Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses? International journal of molecular sciences. 2017;18.

7. Pazaitou-Panayiotou K, Chrisoulidou A, Mandanas S, Tziomalos K, Doumala EPatakiouta F. Predictive factors that influence the course of medullary thyroid carcinoma. International journal of clinical oncology. 2014;19: 445-51.

8. Wells SA, Jr., Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah M, Waguespack SGAmerican Thyroid Association Guidelines Task Force on Medullary Thyroid C. Revised American
Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid: official journal of the American Thyroid Association. 2015;25: 567-610.

9. Raue FF, Frank-Raue K. Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. 2015; 204: 61-90

10. Delellis RA, LiVolsi V, Al Ghuzlan A, X. M-G, Albores Saavedra J, Mete O, Baloch ZW, Moley JF, Basolo F, Nikiforov YE, Elisei R, Nose V, Kaserer KE. PA. Medullary thyroid carcinoma. In: Lloyd RV, Osamura RY, Kloppel G Rosai J (ed) WHO Classification of Tumours of Endocrine Organs, 4th edn. IARC Press, Lyon, France. 2017;108-13.

11. Papi G, Corrado SL, LiVolsi VA. Primary spindle cell lesions of the thyroid gland; an overview. American journal of clinical pathology. 2006;125 Suppl: S95-123.